Abstract
Invasive prolactinoma is a relatively infrequent variety of macroprolactinoma characterized by a fast and aggressive growth, with infiltration to adjacent structures, and whose management is frequently difficult. We present the case of a fatal invasive macroprolactinoma in whom resistance to different dopaminergic drugs developed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vance M.L., Cragun J.R., Reimnitz C., Chang R.J., Rashef E., Blackwell R.E., Miller M.M., Molitch M.E. CV 205–502 treatment of hyperprolactinemia. J. Clin. Endocrinol. Metab. 68: 336, 1989.
Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O. and the Bromocriptine Study Group. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60: 698, 1985.
Chiodini P., Liuzzi A., Cozzi R., Verde G., Oppizzi G., Dallabonzana D., Spelta B., Silvestrini F., Borghi G., Luccarelli G., Rainer E., Horowski R. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J. Clin. Endocrinol. Metab. 53: 737, 1981.
Cunnah D., Besser M. Management of prolactinomas. Clin. Endocrinol. (Oxf.) 34: 231, 1991.
Wass J.A.H, Williams J., Charlesworth M., Kingsley D.P.E., Halliday A.M., Doniach I., Rees L.H., McDonald W.I., Besser G.M. Bromocriptine in management in large pituitary tumours. Br. Med. J. 284: 1908, 1982.
Klibanski A., Zervas N.T. Diagnosis and management of hormone-secreting pituitary adenomas. N. Engl. J. Med. 324: 822, 1991.
Crosignani P.G., Ferrari C., Liuzzi A., Benco R., Mattei A., Rampini P., Dallabonzana D., Scarduelli C., Spelta B. Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline and lisuride. Fertil. Steril. 37: 61, 1982.
Chiodini P.G., Liuzzi A., Verde G., Cozzi R., Silvestrini F., Marsili M.T., Horowski R., Passerini F., Luccarelli G., Borghi P.G. Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisuride. Clin. Endocrinol. (Oxf.) 12: 47, 1980.
Anonymous. Management of prolactinoma. Lancet 336: 661, 1990.
Van’t Verlaat J.W., Lancrajan I., Hendrics M.J., Croughs R.J.M. Primary treatment of prolactinomas with Parlodel LAR. Acta Endocrinol. (Copenh.) 119: 51, 1988.
Schettini G., Lombardi G., Merola B., Colao A., Miletto P., Caruso E., Lancranjan I. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinoma after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). Clin. Endocrinol. (Oxf.) 33: 161, 1990.
Rasmussen C., Bergh T., Wide L., Brownell J. CV 205–502: a new long-acting drug for inhibition of prolactin hypersecretion. Clin. Endocrinol. (Oxf.) 26: 321, 1987.
Serri O., Beauregard H., Lesage J., Pedneault L., Comtois R., Jilwan N., Somma M., Vachon L., Brownell J. Long term treatment with CV 205–502 in patients with prolactin-secreting pituitary macroadenomas. J. Clin. Endorinol. Metab. 71: 682, 1990.
Barnett P.S., Dawson J.M., Butler J., Coskeran P.B., Maccabe J.J., McGregor A.M. CV 205–502, a new non-ergot dopamine agonist, reduces prolactinoma size in man. Clin. Endocrinol. (Oxf.) 33: 307, 1990.
Van’t Verlaat J.W., Croughs R.J.M., Brownell J. Treatment of macroprolactinomas with a new nonergot, long-acting dopaminergic drug, CV 205–502. Clin. Endocrinol. (Oxf.) 33: 619, 1990.
Van der Lely A.J., Brownell J., Lamberts S.W.J. The efficacy and tolerability of CV 205–502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J. Clin. Endocrinol. Metab. 72: 1136, 1991.
Martin N.A., Hales M., Wilson C.B. Cerebellar metastasis from a prolactinoma during treatment with bromocriptine. J. Neurosurg. 55: 615, 1981.
Cohen D.L., Diengdoh J.V., Thomas D.G.T., Himsworth R.L. An intracranial metastasis from a PRL secreting pituitary tumour. Clin. Endocrinol. (Oxf.) 18: 259, 1983.
Gessre R.W., Finkenstedt G., Skrabal F., Twerdy K., Grunert V., Mayr U., Frommhold H., Zur Nedden D., Feichtinger J., Hofstaedter F. Multiple intracranial metastases from a prolactin secreting pituitary tumour. Clin. Endocrinol. (Oxf.) 22: 17, 1985.
Scheithauer B.W., Randall R.V., Laws E.R., Kovacs K.T., Horvath E., Whitaker M.D. Prolactin cell carcinoma of the pitiutary. Cancer 55: 598, 1985.
Muhr C., Bergström M., Lundberg P.O., Hartman M., Bergström K., Pelletieri L., Langström B. Malignant prolactinoma with multiple intracranial metastases studied with Positron Emission Tomography. Neurosurgery 22: 374, 1988.
Popovic E.A., Vattuone J.R., Siu K.H., Busmanis I., Pullar M.J., Dowling J. Malignant prolactinomas. Neurosurgery 29: 127, 1991.
Terry R.D., Hyams V.J., Davidoff L.M. Combined non-metastasizing fibrosarcoma and cromophobe tumour of the pituitary. Cancer 12: 791, 1959.
Pellegrini I., Rasolonjanahary R., Gunz G., Bertrand P., Delivet S., Jedynak C.P., Kordon C., Peillon F., Jaquet P., Enjalbert A. Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab. 69: 500, 1989.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schwarzstein, D., García-Patterson, A., Giménez, G. et al. Dopaminergic resistance in a case of invasive macroprolactinoma. J Endocrinol Invest 16, 443–447 (1993). https://doi.org/10.1007/BF03348879
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348879